Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apotea AB (publ)CHIX:APOTES 18 5-Year Yield-on-Cost % is 0.00 as of Jul. 21, 2026. GuruFocus rates CHIX:APOTES with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 279 Healthcare Providers & Services companies, Apotea AB (publ) ranks worse than 84.23% on this metric.
Apotea AB (publ)'s yield on cost for the quarter that ended in Jun. 2026 was 0.00.
The historical rank and industry rank for Apotea AB (publ)'s 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 5 years, Apotea AB (publ)'s highest Yield on Cost was 0.80. The lowest was 0.75. And the median was 0.77.
CHIX:APOTEs's 5-Year Yield-on-Cost % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.93 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Apotea AB (publ) (CHIX:APOTEs) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Apotea AB (publ) 5-Year Yield-on-Cost % Related Terms
Apotea AB (publ) 5-Year Yield-on-Cost % Competitor Comparison
For the Pharmaceutical Retailers subindustry, Apotea AB (publ)'s 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apotea AB (publ) 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Apotea AB (publ)'s 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Apotea AB (publ)'s 5-Year Yield-on-Cost % falls into.
Apotea AB (publ) 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Apotea AB (publ) (CHIX:APOTES) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 21, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Apotea AB (publ) and its competitors. Over the past decade, Apotea AB (publ)'s 5-Year Yield-on-Cost % has ranged from 0.75 to 0.80. According to the industry distribution chart, Apotea AB (publ) ranks #235 out of 279 companies in the Healthcare Providers & Services industry, placing it in the top 84.2%.
Is Apotea AB (publ)'s 5-Year Yield-on-Cost % too high?
Apotea AB (publ)'s current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.75 to a high of 0.80. Based on the distribution chart, Apotea AB (publ) ranks #235 out of 279 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Apotea AB (publ) has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Apotea AB (publ)'s 5-Year Yield-on-Cost % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Apotea AB (publ) ranks #235 out of 279 companies for 5-Year Yield-on-Cost %. This places Apotea AB (publ) in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.93. Historically, Apotea AB (publ)'s own 5-Year Yield-on-Cost % has ranged from 0.75 to 0.80 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.93, based on 279 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Apotea AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apotea AB (publ)'s current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apotea AB (publ) stock overvalued right now?
Apotea AB (publ) (CHIX:APOTES) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Apotea AB (publ)'s overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Apotea AB (publ) (CHIX:APOTES), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apotea AB (publ) is engaged in the online pharmacy with fast deliveries, good prices and a large selection. Its vision is to be tomorrow's pharmacy by constantly facilitating and simplifying for the customer.
18GF Score
Get the complete analysis for CHIX:APOTES
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:APOTES has been successfully added to your 
